Condition (MeSH)
X-Linked Combined Immunodeficiency Diseases
ClinicalTrials.gov lists 28 trials for X-Linked Combined Immunodeficiency Diseases or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 8.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
28 of the 28 trials are tagged with X-Linked Combined Immunodeficiency Diseases itself; the rest are tagged with a narrower condition beneath it.
When did X-Linked Combined Immunodeficiency Diseases trials start? (16)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 1 |
| 2020 | 1 |
| 2019 | 1 |
| 2018 | 3 |
| 2016 | 1 |
| 2015 | 1 |
| 2013 | 1 |
| 2012 | 2 |
| 2011 | 2 |
Showing 10 of 16 earlier years.
No forecast is made for this condition: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are X-Linked Combined Immunodeficiency Diseases trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 4 |
| Phase 1/2 | 10 |
| Not applicable | 2 |
| Observational | 11 |
| Expanded access | 1 |
How many X-Linked Combined Immunodeficiency Diseases trials are recruiting? (9)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 5 |
| Enrolling by invitation | 2 |
| Active, not recruiting | 1 |
| Completed | 8 |
Showing 5 of 9 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most X-Linked Combined Immunodeficiency Diseases trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 8 |
| National Human Genome Research Institute (NHGRI) | 3 |
| Phenox GmbH | 2 |
| Celgene Corporation | 1 |
Which drugs are being tested for X-Linked Combined Immunodeficiency Diseases? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Busulfan | 4 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Palifermin before only | 3 |
| Gene transfer | 2 |
| Direct intravenous injection of ivlv-X1 lentiviral vector | 1 |
| Ex vivo culture and transduction of the patient's autologous CD34+ HSC with lentivirus vector VSV-G pseudotyped CL20- 4i-EF1alpha-hgammac-OPT vector | 1 |
| Filgrastime (G-CSF) | 1 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do X-Linked Combined Immunodeficiency Diseases trials report? (6)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| BCGosis | 1 | 1 |
| E. Coli and Klebsiella Infection | 1 | 1 |
| Pseudomonas/Stenotrophomonas Infection | 1 | 1 |
| Rhinovirus | 1 | 1 |
| Upper respiratory infection | 1 | 1 |
Showing 5 of 6 adverse events.
Which publications cover X-Linked Combined Immunodeficiency Diseases? (14)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| A Double-Blind, Placebo-Controlled, Crossover Study of Magnesium Supplementation in Patients with XMEN Disease. | Journal of clinical immunology | 2022 | Yes |
| Lentivector cryptic splicing mediates increase in CD34+ clones expressing truncated HMGA2 in human X-linked severe combined immunodeficiency. | Nature communications | 2022 | Yes |
| Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1. | The New England journal of medicine | 2019 | Yes |
| T cell dynamics and response of the microbiota after gene therapy to treat X-linked severe combined immunodeficiency. | Genome medicine | 2018 | Yes |
| Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency. | Science translational medicine | 2016 | Yes |
Showing 5 of 14 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.